Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 2:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 17,835 matching trials from the live ClinicalTrials.gov search.
Conditions
Schizophrenia
Interventions
BL-1020, BL-1020 10-30 mg, risperidone
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Irvine, California
Conditions
HCV Infection
Interventions
ABT-072, ketoconazole, Placebo
Drug · Other
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Conditions
Actinic Keratosis
Interventions
KX2-391 Ointment 1%, Placebo
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 27 more
Conditions
CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type, Anaplastic Large Cell Lymphoma, ALK-Positive, Peripheral T-cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-negative, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
C7R.CD30.CAR-EBVST cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2043
U.S. locations
2
States / cities
Houston, Texas
Conditions
Healthy
Interventions
Empagliflozin/Metformin XR FDC, 25 mg Empagliflozin/1000 mg Metformin XR, FDC, 1 tablet Empagliflozin/2 tablets Metformin XR, 1 tablet Empagliflozin/3 tablets Metformin XR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Conditions
Idiopathic CD4 Lymphopenia
Interventions
Recombinant human interleukin (IL) 7-hyFc
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
Conditions
Histoplasmosis
Interventions
LAmB B, Posaconazole, World Health Organization (WHO)-recommended SOC, WHO-recommended SOC Itraconazole
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Healthy
Interventions
AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
Drug
Lead sponsor
Cerecin
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions
yttrium Y 90-edotreotide
Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Healthy
Interventions
Placebo, 611
Drug
Lead sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
48
States / cities
Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more
Conditions
Healthy
Interventions
K-877, CSG452
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Conditions
Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired
Interventions
Amifampridine Phosphate
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Healthy
Interventions
V330, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 79 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Glendale, California • Hallandale, Florida • Hollywood, Florida + 1 more
Conditions
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions
clofarabine, melphalan, allogeneic hematopoietic stem cell transplantation, tacrolimus, sirolimus, Pharmacological Study
Drug · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Duarte, California
Completed Phase 2 Interventional Results available

Oral Testosterone for the Treatment of Hypogonadism

NCT01717768
Conditions
Hypogonadism
Interventions
TSX-002
Drug
Lead sponsor
TesoRx Pharma, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Brain Cancer
Interventions
Nivolumab, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more
Conditions
Head and Neck Cancer, Head and Neck Small Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions
Pembrolizumab, Definity, Ultrasound-Induced Microbubble Cavitation
Drug · Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Triple Negative Breast Cancer
Interventions
Pembrolizumab, INBRX-106
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Los Angeles, California • Portland, Oregon
Conditions
Respiratory Syncytial Virus Infections
Interventions
JNJ-53718678, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
28 Days to 3 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Madera, California • Ventura, California • Aurora, Colorado + 11 more
Conditions
Pancreatic Cancer, Adult
Interventions
Gemcitabine, nab-paclitaxel, NPC-1C
Drug
Lead sponsor
Precision Biologics, Inc
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 7 more
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
cytarabine, deoxycytidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Postoperative Pain
Interventions
Bupivacaine Collagen Sponge (CollaRx®), placebo
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina